Vanta Bioscience Limited (BOM:540729)
India
· Delayed Price · Currency is INR 27.79
+0.50 (1.83%)
At close: Jun 17, 2025
Vanta Bioscience Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2018 - 2019 |
Net Income | -38.48 | -23.16 | -64.81 | 0.88 | 4.5 | 10.05 | Upgrade
|
Depreciation & Amortization | 46.4 | 44.97 | 26.7 | 13.16 | 12.51 | 11.89 | Upgrade
|
Loss (Gain) From Sale of Assets | -0.42 | -0.42 | - | - | -0.22 | - | Upgrade
|
Other Operating Activities | -18.1 | -7.62 | 21.04 | 24.87 | 22.79 | 22.86 | Upgrade
|
Change in Accounts Receivable | -3.63 | -11.82 | -8.25 | 8.81 | -6.23 | 1.73 | Upgrade
|
Change in Inventory | -19.1 | -3.63 | 0.78 | 25.29 | 42.43 | -47.63 | Upgrade
|
Change in Other Net Operating Assets | 24.59 | 28.52 | 18.26 | -20.22 | -6.07 | 24.53 | Upgrade
|
Operating Cash Flow | -8.74 | 26.84 | -6.28 | 52.79 | 69.72 | 23.41 | Upgrade
|
Operating Cash Flow Growth | - | - | - | -24.29% | 197.82% | - | Upgrade
|
Capital Expenditures | -33.9 | -34.05 | -286.89 | -171.81 | -221.94 | -73.52 | Upgrade
|
Sale of Property, Plant & Equipment | 0.92 | 0.92 | - | - | - | - | Upgrade
|
Other Investing Activities | -0 | -0 | 227.8 | - | - | - | Upgrade
|
Investing Cash Flow | -32.98 | -33.13 | -59.09 | -171.81 | -221.94 | -73.52 | Upgrade
|
Short-Term Debt Issued | - | 11.05 | 5.13 | - | 22.68 | 12.84 | Upgrade
|
Long-Term Debt Issued | - | 77.19 | 117.81 | 92.28 | 163.32 | 28.39 | Upgrade
|
Total Debt Issued | 136.47 | 88.24 | 122.95 | 92.28 | 186 | 41.23 | Upgrade
|
Short-Term Debt Repaid | - | - | - | -3.32 | - | - | Upgrade
|
Long-Term Debt Repaid | - | -50.32 | - | - | - | - | Upgrade
|
Total Debt Repaid | -49.4 | -50.32 | - | -3.32 | - | - | Upgrade
|
Net Debt Issued (Repaid) | 87.07 | 37.92 | 122.95 | 88.97 | 186 | 41.23 | Upgrade
|
Issuance of Common Stock | 5 | 26.5 | - | 29.82 | 13.2 | - | Upgrade
|
Other Financing Activities | -50.44 | -57.49 | -58.86 | -23.47 | -21.4 | -19.48 | Upgrade
|
Financing Cash Flow | 41.64 | 6.93 | 64.09 | 95.32 | 177.81 | 21.75 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 0.36 | 0 | - | -0.56 | -1.03 | -2.35 | Upgrade
|
Net Cash Flow | 0.27 | 0.64 | -1.28 | -24.26 | 24.55 | -30.71 | Upgrade
|
Free Cash Flow | -42.64 | -7.21 | -293.17 | -119.02 | -152.22 | -50.11 | Upgrade
|
Free Cash Flow Margin | -92.95% | -7.41% | -467.13% | -118.81% | -151.45% | -35.43% | Upgrade
|
Free Cash Flow Per Share | -6.76 | -1.14 | -46.45 | -18.86 | -24.12 | -7.94 | Upgrade
|
Cash Interest Paid | 50.18 | 57.23 | 56.05 | 23.47 | 20.61 | 19.2 | Upgrade
|
Levered Free Cash Flow | -52.75 | -34.07 | -323.16 | -130.68 | -175.86 | -91.56 | Upgrade
|
Unlevered Free Cash Flow | -21.38 | 1.7 | -288.13 | -116.01 | -162.98 | -79.57 | Upgrade
|
Change in Net Working Capital | -2.02 | -10.56 | -3.71 | -27.12 | -29.19 | 37.82 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.